Radiation therapy for carcinoma of the prostate

Abstract

The results of megavolt age radiotherapy by linear accelerator for the prostatic cancer are reported. Most of the patients were treated with combined radiation and hormone therapy. Five‐year survival rates in stages B, C, and D were 91.7%, 58.9%, and 25.3%, respectively. Patients with stage C disease did poorly following radiotherapy compared to stage A and B patients. Improvement of overall status and atrophy of prostatic lesions was more frequently observed in stage B than in stage C disease. The post‐therapeutic course was good in those patients in whom the prostate atrophied, and when this was combined with an absence of detectable cancer cells, the post‐therapeutic course was excellent. Many patients who experienced only general improvement or no change in prostate size after irradiation experienced reactivation or developed metastasis.

Transurethral Resection in the Management of Urethral and Prostatic Neoplasia in 6 Dogs

“…These survival times are not different than the 32 to 264 days for the dogs with prostatic carcinomas in the present series and it can be argued that the addition of TUR to the management protocol may not have provided a survival benefit. However, radiation‐induced responses in prostatic size are slow 55 and, in the dogs described herein, TUR provided rapid relief of urinary obstruction and improvement in quality of life.…”